MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF

1 - 41 . (canceled)

42 . A modified therapeutic agent (mTA) of Formula (I):

wherein:

TA is a therapeutic agent, wherein the therapeutic agent is a single peptide comprising an amino acid sequence that is at least 95% homologous to any one of SEQ ID NO: 7 and 12-30;

Q is

A 1 is

P 1 is PEG-A 2 ; wherein:

PEG is

m and n are each 1, 2, 3, or 4; and

A 2 is

L is a lipid derivative selected from a group consisting of sterols, bile acids, vitamin E, fatty di-acids, fatty acids, fatty amides, fatty amines, and fatty alcohols;

a is 1; and

b is 1;

wherein the TA is covalently attached to Q via two amine-containing sidechain amino acids on the single peptide; and wherein the two amine-containing sidechain amino acids are at least two amino acids apart, and less than 20 amino acids apart.

43 . The mTA of claim 42 , wherein the two amine-containing sidechain amino acids are 6 amino acids apart.

44 . The mTA of claim 42 , wherein each of the two amine-containing sidechain amino acids is lysine.

45 . The mTA of claim 42 , wherein-Q-A 1 -P 1 -L is:

46 . The mTA of claim 42 , wherein the single peptide is an exendin-4 agonist, GLP-1R agonist, GLP-2R agonist, GLP-1R/GCGR dual agonist, GLP-1R/GIPR dual agonist, or GLP-1R/GCGR/GIPR tri-agonist.

47 . The mTA of claim 42 , wherein the single peptide is an exendin-4 agonist.

48 . The mTA of claim 42 , wherein the single peptide has an amino acid sequence that is at least 95% homologous to SEQ ID NO: 7.

49 . The mTA of claim 42 , wherein the single peptide is an GLP-1R/GCGR dual agonist.

50 . The mTA of claim 42 , wherein the single peptide has an amino acid sequence that is at least 95% homologous to SEQ ID NO: 15.

51 . The mTA of claim 42 , wherein the single peptide is a GLP-2R agonist.

52 . The mTA of claim 42 , wherein the single peptide has an amino acid sequence that is at least 95% homologous to SEQ ID NO: 26.

53 . A pharmaceutical composition comprising the mTA of claim 42 , and a pharmaceutically acceptable excipient.

54 . A method for treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of the mTA of claim 42 , wherein the disease or condition is diabetes, obesity, or a medical condition associated with diabetes or obesity,

55 . A method for treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of the mTA of claim 42 , wherein the disease or condition is cardiovascular disease, psoriasis, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, inflammatory bowel syndrome, or short bowel syndrome.

56 . A modified therapeutic agent (mTA) comprising (i) a therapeutic agent, (ii) a half-life extending molecule, and (iii) a staple, wherein:

(i) the therapeutic agent is a single peptide chain having an amino acid sequence that is at least 95% homologousto any one of SEQ ID NOs: 7 and 12-30 that is covalently attached to the staple via two amine-containing sidechain amino acids on the single peptide chain; and

wherein the two amine-containing sidechain amino acids are at least two amino acids apart, and less than 20 amino acids apart;

(ii) the half-life extending molecule is covalently attached to the first staple; and

(iii) the staple has the following structure:

57 . The mTA of claim 56 , wherein the staple and the half-life extending molecule have a structure according to L 4 , L 5 , L 6 , or L 7 :

58 . A modified therapeutic agent (mTA) comprising (i) a therapeutic agent, (ii) a half-life extending molecule, and (iii) a staple, wherein:

(i) the therapeutic agent is a single peptide GLP-1R/GCGR/GIPR tri-agonist that is covalently attached to the staple via two amine-containing sidechain amino acids on the single peptide; wherein the two amine-containing sidechain amino acids are at least two amino acids apart, and less than 20 amino acids apart;

(ii) the half-life extending molecule is covalently attached to the first staple; and

(iii) the staple has the following structure:

59 . The mTA of claim 58 , wherein the half-life extending molecule comprises a lipid, a polyglycol, a peptide, or a combination thereof.

60 . The mTA of claim 59 , wherein the lipid is a fatty diacid, fatty acid, fatty amide, fatty amine, or fatty alcohol having 10 to 40 carbon atoms.

61 . The mTA of claim 59 , wherein the lipid is selected from dodecanoic acid, dodecanedioic acid, tridecanoic acid, tridecanedioic acid, tetradecanoic acid, tetradecanedioic acid, myristic acid, pentadecanoic acid, pentadecanedioic acid, hexadecanoic acid, hexadecanedioic acid, heptadecanoic acid, heptadecanedioic acid, octadecanoic acid, octadecanedioic acid, nonadecanoic acid, nonadecanedioic acid, eicosanoic acid, or eicosanedioic acid.